NFE2L2 and lung adenocarcinoma: Genes in the KEAP1-NFE2L2 pathway are mutated in ~33% of lung squamous cell carcinoma and ~22% of lung adenocarcinoma [126], which agrees with our results indication the presence of NFE2L2 as activated upstream regulator both in ADC and SCC.